Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Regulation of sagA, siaA and scpC by SilCR, a putative signaling peptide of Streptococcus pyogenes.

Salim KY, de Azavedo JC, Bast DJ, Cvitkovitch DG.

FEMS Microbiol Lett. 2008 Dec;289(2):119-25. doi: 10.1111/j.1574-6968.2008.01375.x. Epub 2008 Oct 29.

2.

The two-component system sivS/R regulates virulence in Streptococcus iniae.

Bolotin S, Fuller JD, Bast DJ, de Azavedo JC.

FEMS Immunol Med Microbiol. 2007 Dec;51(3):547-54.

3.

Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia.

De Azavedo JC, Dresser L, Duncan CL, Walker SE, Low DE, Bast DJ.

J Chemother. 2007 Aug;19(4):392-7.

PMID:
17855183
4.

Role for sagA and siaA in quorum sensing and iron regulation in Streptococcus pyogenes.

Salim KY, de Azavedo JC, Bast DJ, Cvitkovitch DG.

Infect Immun. 2007 Oct;75(10):5011-7. Epub 2007 Jul 16.

5.

Capsule expression regulated by a two-component signal transduction system in Streptococcus iniae.

Bolotin S, Fuller JD, Bast DJ, Beveridge TJ, de Azavedo JC.

FEMS Immunol Med Microbiol. 2007 Aug;50(3):366-74. Epub 2007 May 30.

6.

Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.

Bast DJ, Dresser L, Duncan CL, Walker SE, Mandell LA, Low DE, de Azavedo JC.

J Chemother. 2006 Dec;18(6):634-40.

PMID:
17267342
7.

Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.

De Azavedo JC, Duncan CL, Kilburn L, Downar J, Kong B, Lad S, Low DE, Bast DJ.

J Chemother. 2006 Aug;18(4):373-8.

PMID:
17024792
8.

Identification of group A Streptococcus antigenic determinants upregulated in vivo.

Salim KY, Cvitkovitch DG, Chang P, Bast DJ, Handfield M, Hillman JD, de Azavedo JC.

Infect Immun. 2005 Sep;73(9):6026-38.

9.

Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.

Powis J, McGeer A, Duncan C, Goren R, de Azavedo JC, Bast DJ, Pong-Porter S, Mazzulli T, Green K, Willey B, Low DE.

Antimicrob Agents Chemother. 2005 May;49(5):2130-2.

10.

Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.

Bast DJ, Yue M, Chen X, Bell D, Dresser L, Saskin R, Mandell LA, Low DE, de Azavedo JC.

Antimicrob Agents Chemother. 2004 Sep;48(9):3343-8.

11.

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.

Bast DJ, Athamna A, Duncan CL, de Azavedo JC, Low DE, Rahav G, Farrell D, Rubinstein E.

J Antimicrob Chemother. 2004 Jul;54(1):90-4. Epub 2004 Jun 9.

PMID:
15190035
12.

Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease.

Fuller JD, Camus AC, Duncan CL, Nizet V, Bast DJ, Thune RL, Low DE, De Azavedo JC.

Infect Immun. 2002 Oct;70(10):5730-9.

13.

Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Gershon AS, de Azavedo JC, McGeer A, Ostrowska KI, Church D, Hoban DJ, Harding GK, Weiss K, Abbott L, Smaill F, Gourdeau M, Murray G, Low DE; Canadian Bacterial Surveillance Network.

Antimicrob Agents Chemother. 2002 May;46(5):1553-6.

14.

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

Low DE, Muller M, Duncan CL, Willey BM, de Azavedo JC, McGeer A, Kreiswirth BN, Pong-Porter S, Bast DJ.

Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21.

15.

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE.

N Engl J Med. 2002 Mar 7;346(10):747-50. No abstract available.

16.

Streptolysin S and necrotising infections produced by group G streptococcus.

Humar D, Datta V, Bast DJ, Beall B, De Azavedo JC, Nizet V.

Lancet. 2002 Jan 12;359(9301):124-9.

PMID:
11809255
17.

Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.

de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A.

Antimicrob Agents Chemother. 2001 Dec;45(12):3504-8.

18.

Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Bast DJ, de Azavedo JC, Tam TY, Kilburn L, Duncan C, Mandell LA, Davidson RJ, Low DE.

Antimicrob Agents Chemother. 2001 Sep;45(9):2631-4.

19.

Streptococcus iniae virulence is associated with a distinct genetic profile.

Fuller JD, Bast DJ, Nizet V, Low DE, de Azavedo JC.

Infect Immun. 2001 Apr;69(4):1994-2000.

20.

Quinolone Resistance: Older Concepts and Newer Developments.

Bast DJ, de Azavedo JC.

Curr Infect Dis Rep. 2001 Feb;3(1):20-28.

PMID:
11177727
21.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, de Azavedo JC.

Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54.

22.

Genetic locus for streptolysin S production by group A streptococcus.

Nizet V, Beall B, Bast DJ, Datta V, Kilburn L, Low DE, De Azavedo JC.

Infect Immun. 2000 Jul;68(7):4245-54.

23.

In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

de Azavedo JC, Trpeski L, Pong-Porter S, Matsumura S, Low DE.

Antimicrob Agents Chemother. 1999 Sep;43(9):2299-301.

24.

Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

De Azavedo JC, Yeung RH, Bast DJ, Duncan CL, Borgia SB, Low DE.

Antimicrob Agents Chemother. 1999 Sep;43(9):2144-7.

25.
26.
27.

Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S.

Betschel SD, Borgia SM, Barg NL, Low DE, De Azavedo JC.

Infect Immun. 1998 Apr;66(4):1671-9.

28.

Cloning of a chromosomal region responsible for streptolysin S production in Streptococcus pyogenes.

Borgia SM, Betschel S, Low DE, de Azavedo JC.

Adv Exp Med Biol. 1997;418:733-6. No abstract available.

PMID:
9331756
29.

Association of transposon Tn1545 with multidrug resistant strains of Streptococcus pneumoniae isolated in Canada.

de Azavedo JC, Pieroni P, Chang P, Low DE.

Adv Exp Med Biol. 1997;418:475-8. No abstract available.

PMID:
9331697
30.

Heterogeneity in phenotypic and genotypic characteristics among strains of Hafnia alvei.

Ismaili A, Bourke B, de Azavedo JC, Ratnam S, Karmali MA, Sherman PM.

J Clin Microbiol. 1996 Dec;34(12):2973-9.

31.

Expression and characterization of the eaeA gene product of Escherichia coli serotype O157:H7.

Louie M, de Azavedo JC, Handelsman MY, Clark CG, Ally B, Dytoc M, Sherman P, Brunton J.

Infect Immun. 1993 Oct;61(10):4085-92.

32.

A toxic shock syndrome toxin mutant of Staphylococcus aureus isolated by allelic replacement lacks virulence in a rabbit uterine model.

Sloane R, de Azavedo JC, Arbuthnott JP, Hartigan PJ, Kreiswirth B, Novick R, Foster TJ.

FEMS Microbiol Lett. 1991 Mar 1;62(2-3):239-44.

PMID:
2040432
33.

Damaging effect of toxic shock syndrome toxin 1 on chick embryo cells in vitro.

Drumm A, de Azavedo JC, Arbuthnott JP.

Rev Infect Dis. 1989 Jan-Feb;11 Suppl 1:S275-80; discussion S280-1.

PMID:
2928645
34.

Animal models for toxic shock syndrome: overview.

de Azavedo JC.

Rev Infect Dis. 1989 Jan-Feb;11 Suppl 1:S205-9. Review. No abstract available.

PMID:
2648539
35.

Induction of tumour necrosis factor by staphylococcal toxic shock toxin 1.

de Azavedo JC, Drumm A, Jupin C, Parant M, Alouf JE, Arbuthnott JP.

FEMS Microbiol Immunol. 1988 Jul;1(2):69-74.

PMID:
3273461
36.

Chick embryo assay for staphylococcal toxic shock syndrome toxin-1.

de Azavedo JC, Lucken RN, Arbuthnott JP.

Methods Enzymol. 1988;165:344-7. No abstract available.

PMID:
3231112
37.

Purification of epidermolytic toxin of Staphylococcus aureus.

de Azavedo JC, Bailey CJ, Arbuthnott JP.

Methods Enzymol. 1988;165:32-6. No abstract available.

PMID:
3231110
38.

Assays for epidermolytic toxin of Staphylococcus aureus.

de Azavedo JC, Arbuthnott JP.

Methods Enzymol. 1988;165:333-8. No abstract available.

PMID:
3148097
39.

Toxic shock syndrome in a penicillin sensitive patient.

Barry M, Mac MathĂșna P, de Azavedo JC, Feely J.

Ir J Med Sci. 1987 Jan;156(1):18-9. No abstract available.

PMID:
3557915
40.
41.

Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model.

de Azavedo JC, Foster TJ, Hartigan PJ, Arbuthnott JP, O'Reilly M, Kreiswirth BN, Novick RP.

Infect Immun. 1985 Oct;50(1):304-9.

42.

Effect of toxic shock syndrome toxin 1 on chicken embryos.

de Azavedo JC, Lucken RN, Arbuthnott JP.

Infect Immun. 1985 Mar;47(3):710-2.

43.

Gram-negative endotoxins and staphylococcal toxic shock syndrome.

de Azavedo JC, Hartigan PJ, de Saxe M, Arbuthnott JP.

Prog Clin Biol Res. 1985;189:419-32.

PMID:
4048216
44.

Toxicity of staphylococcal toxic shock syndrome toxin 1 in rabbits.

de Azavedo JC, Arbuthnott JP.

Infect Immun. 1984 Nov;46(2):314-7.

Supplemental Content

Loading ...
Support Center